Home › Mild Cognitive Impairment › NCT06307574

bpMedManage: Digital Technology to Support Adherence to Hypertension Medications

Digital Technology to Support Adherence to Hypertension Medications for Older Adults With Mild Cognitive Impairment

Who can join

Ages 60 and older · All sexes

Inclusion Criteria:

1. Age 60+
2. Community-dwelling older adults
3. Self-reported fluent in English
4. Adequate self-reported visual and hearing ability
5. Self-reported memory, thinking, or concentration challenges
6. Self-manage at least one prescribed antihypertensive medication
7. Have and use a smartphone
8. No self-reported history of major depression or other mental health diagnoses
9. No self-reported diagnosis of dementia or other neurological disorder such as stroke, TBI, and Parkinson's disease
10. TICS-M score between 27-37 and Montreal Cognitive Assessment (MoCA) score between 20-26
11. Willing to participate in the study for at least 4 months

Exclusion Criteria:

1. Diagnosis of dementia
2. Lives in assisted living facility or skilled nursing facility

About the study

The purpose of the bpMedManage study is to rigorously test the efficacy of a smartphone technology to help improve high blood pressure medication adherence among older adults with mild cognitive impairment (MCI) in a 16-week randomized controlled trial. A total of 100 older adults will be recruited. There will be two treatment arms, bpMedManage-S and bpMedManage-P with 50 participants in each arm. Participants randomized into the bpMEDManage-S intervention arm will use a smartphone application with medication reminders plus receive education with standardized information on hypertension and antihypertensive medications on the education portal. Participants in the bpMedManage-P group will use a smartphone to receive education with standardized information on hypertension and antihypertensive medications on an education portal. Both groups will complete baseline assessments followed by 4 weeks of medication adherence monitoring. At the end of the adherence monitoring period, participants will be randomized into one of the two treatment arms. Immediate outcomes on primary and secondary measures will be assessed 4 weeks after beginning of the intervention. Follow-up outcomes will be assessed 12 weeks after the beginning of the intervention.

What is being tested

• bpMedManage (behavioral)

Sponsor: University of Arizona · Participants: 100 · Started: Feb 29, 2024

Contact the study team

• Kathleen Insel, PhD · Phone: 520-626-6220
• Raksha Mudar, PhD · Phone: 217-333-4718

Official record on ClinicalTrials.gov — NCT06307574

Locations in the U.S.

Conditions

• Mild Cognitive Impairment
• High Blood Pressure

From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.